Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer

Oncotarget

Volumn 6, Issue 8, 2015, Pages 6235-6250

  Annala, Matti ^a,b   Kivinummi, Kati ^a,b   Tuominen, Joonas ^a,c   Karakurt, Serdar ^a,c   Granberg, Kirsi ^a,b   Latonen, Leena ^a,c   Ylipää, Antti ^a,b   Sjöblom, Liisa ^a,c   Ruusuvuori, Pekka ^a,b   Saramäki, Outi ^a,c   Kaukoniemi, Kirsi M ^a,c   Yli Harja, Olli ^b   Vessella, Robert L ^d   Tammela, Teuvo L J ^c   Zhang, Wei ^e   Visakorpi, Tapio ^a,c   Nykter, Matti ^a,b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Fusion gene; Prostate cancer; Sequencing; SKIL

Indexed keywords

ANDROGEN; SMAD PROTEIN; TRANSCRIPTION FACTOR ETS; TRANSFORMING GROWTH FACTOR BETA; ONCOPROTEIN; SIGNAL PEPTIDE; SKIL PROTEIN, HUMAN; TRANSCRIPTOME;

ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INHIBITION; CELL INVASION; CONTROLLED STUDY; DRUG TARGETING; GENE; GENE EXPRESSION; GENE FUSION; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; LNCAP CELL LINE; ONCOGENE; PROMOTER REGION; PROSTATE CANCER; PROSTATE CANCER CELL LINE; SIGNAL TRANSDUCTION; SKIL GENE; SPINK1 GENE; TUMOR XENOGRAFT; ANIMAL; BIOSYNTHESIS; CLASSIFICATION; COHORT ANALYSIS; GENETIC TRANSFECTION; GENETICS; MALE; METABOLISM; MIDDLE AGED; MOUSE; PROSTATE TUMOR; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; COHORT STUDIES; GENE KNOCKDOWN TECHNIQUES; GENE REARRANGEMENT; HETEROGRAFTS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MIDDLE AGED; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-ETS; TRANSCRIPTOME; TRANSFECTION;

EID: 84925607557     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3359     Document Type: Article

References (43)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 2011;61(2):69-90.
2. Wong YNS, Ferraldeschi R, Attard G, de Bono J. Evolution of androgen receptor targeted therapy for advanced prostate cancer. Nat. Rev. Clin. Oncol. 2014;11(6):365-76.
3. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18(1):11-22.
4. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat J-P, White TA, Stojanov P, Van Allen E, Stransky N, Nickerson E, Chae S-S, Boysen G, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 2012;44(6):685-9.
5. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun X-W, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310(5748):644-8.
6. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat. Rev. Cancer 2008;8(7):497-511.
7. Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, Demichelis F, Helgeson BE, Laxman B, Morris DS, Cao Q, Cao X, Andrén O, et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 2008;13(6):519-28.
8. Ateeq B, Tomlins SA, Laxman B, Asangani IA, Cao Q, Cao X, Li Y, Wang X, Feng FY, Pienta KJ, Varambally S, Chinnaiyan AM. Therapeutic targeting of SPINK1-positive prostate cancer. Sci. Transl. Med. 2011;3(72):72ra17.
9. Burkhardt L, Fuchs S, Krohn A, Masser S, Mader M, Kluth M, Bachmann F, Huland H, Steuber T, Graefen M, Schlomm T, Minner S, Sauter G, et al. CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res. 2013;73(9):2795-805.
10. Grasso CS, Wu Y-M, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012;487(7406):239-43.
11. Ding Z, Wu C-J, Chu GC, Xiao Y, Ho D, Zhang J, Perry SR, Labrot ES, Wu X, Lis R, Hoshida Y, Hiller D, Hu B, et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011;470(7333):269-73.
12. Qin J, Wu S-P, Creighton CJ, Dai F, Xie X, Cheng C-M, Frolov A, Ayala G, Lin X, Feng X-H, Ittmann MM, Tsai S-J, Tsai M-J, et al. COUP-TFII inhibits TGF-β-induced growth barrier to promote prostate tumorigenesis. Nature 2013;493(7431):236-40.
13. Bjerke GA, Pietrzak K, Melhuish TA, Frierson HF Jr, Paschal BM, Wotton D. Prostate cancer induced by loss of Apc is restrained by TGFβ signaling. PLoS One 2014;9(3):e92800.
14. Aitchison AA, Veerakumarasivam A, Vias M, Kumar R, Hamdy FC, Neal DE, Mills IG. Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer. Prostate 2008;68(6):661-74.
15. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271(5247):350-3.
16. Stroschein SL, Wang W, Zhou S, Zhou Q, Luo K. Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein. Science 1999;286(5440):771-4.
17. Sun Y, Liu X, Ng-Eaton E, Lodish HF, Weinberg RA. SnoN and Ski protooncoproteins are rapidly degraded in response to transforming growth factor beta signaling. Proc. Natl. Acad. Sci. U. S. A. 1999;96(22):12442-7.
18. Cho N-Y, Choi M, Kim B-H, Cho Y-M, Moon KC, Kang GH. BRAF and KRAS mutations in prostatic adenocarcinoma. Int. J. Cancer 2006;119(8):1858-62.
19. Lindhurst MJ, Sapp JC, Teer JK, Johnston JJ, Finn EM, Peters K, Turner J, Cannons JL, Bick D, Blakemore L, Blumhorst C, Brockmann K, Calder P, et al. A Mosaic Activating Mutation in AKT1 Associated with the Proteus Syndrome. N. Engl. J. Med. 2011;365(7):611-9.
20. Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, Wiley KE, Isaacs SD, Johng D, Wang Y, Bizon C, Yan G, Gielzak M, et al. Germline Mutations in HOXB13 and Prostate-Cancer Risk. N. Engl. J. Med. 2012;366(2):141-9.
21. Ramos-Montoya A, Lamb AD, Russell R, Carroll T, Jurmeister S, Galeano-Dalmau N, Massie CE, Boren J, Bon H, Theodorou V, Vias M, Shaw GL, Sharma NL, et al. HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network. EMBO Mol. Med. 2014;6(5):651-61.
22. Annala M, Kivinummi K, Leinonen K, Tuominen J, Zhang W, Visakorpi T, Nykter M. DOT1L-HES6 fusion drives androgen independent growth in prostate cancer. EMBO Mol. Med. 2014;6(9):1121-3.
23. Nomura N, Sasamoto S, Ishii S, Date T, Matsui M, Ishizaki R. Isolation of human cDNA clones of ski and the ski-related gene, sno. Nucleic Acids Res. 1989;17(14):5489-500.
24. Pearson-White S. Snol, a novel alternatively spliced isoform of the ski protooncogene homolog, sno. Nucleic Acids Res. 1993;21(19):4632-8.
25. Li Y, Turck CM, Teumer JK, Stavnezer E. Unique sequence, ski, in Sloan-Kettering avian retroviruses with properties of a new cell-derived oncogene. J. Virol. 1986;57(3):1065-72.
26. Boyer PL, Colmenares C, Stavnezer E, Hughes SH. Sequence and biological activity of chicken snoN cDNA clones. Oncogene 1993;8(2):457-66.
27. Deheuninck J, Luo K. Ski and SnoN, potent negative regulators of TGF-β signaling. Cell Res. 2008;19(1):47-57.
28. Hagerstrand D, Tong A, Schumacher SE, Ilic N, Shen RR, Cheung HW, Vazquez F, Shrestha Y, Kim SY, Giacomelli AO, Rosenbluh J, Schinzel AC, Spardy NA, et al. Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. Cancer Discov. 2013;3(9):1044-57.
29. Wu JW, Krawitz AR, Chai J, Li W, Zhang F, Luo K, Shi Y. Structural mechanism of Smad4 recognition by the nuclear oncoprotein Ski: insights on Ski-mediated repression of TGF-beta signaling. Cell 2002;111(3):357-67.
30. Band AM, Laiho M. SnoN oncoprotein enhances estrogen receptor-α transcriptional activity. Cell. Signal. 2012;24(4):922-30.
31. Dubbink HJ, Hersmus R, Pike ACW, Molier M, Brinkmann AO, Jenster G, Trapman J. Androgen receptor ligand-binding domain interaction and nuclear receptor specificity of FXXLF and LXXLL motifs as determined by L/F swapping. Mol. Endocrinol. 2006;20(8):1742-55.
32. Maher CA, Kumar-Sinha C, Cao X, Kalyana-Sundaram S, Han B, Jing X, Sam L, Barrette T, Palanisamy N, Chinnaiyan AM. Transcriptome sequencing to detect gene fusions in cancer. Nature 2009;458(7234):97-101.
33. Bolton NJ, Lahtonen R, Vihko P, Kontturi M, Vihko R. Androgens and prostate-specific acid phosphatase in whole tissue and in separated epithelium from human benign prostatic hypertrophic glands. Prostate 1981;2(4):409-16.
34. Cerveira N, Ribeiro FR, Peixoto A, Costa V, Henrique R, Jerónimo C, Teixeira MR. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 2006;8(10):826-32.
35. Corey E, Vessella RL. Xenograft models of human prostate cancer. In: Prostate cancer. Springer; 2007. page 3-31.
36. Iyer MK, Chinnaiyan AM, Maher CA. ChimeraScan: A tool for identifying chimeric transcription in sequencing data. Bioinformatics 2011;27(20):2903-4.
37. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10(3):R25.
38. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg S. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14(4):R36.
39. Venkatachalan SP, Bushman JD, Mercado JL, Sancar F, Christopherson KR, Boileau AJ. Optimized expression vector for ion channel studies in Xenopus oocytes and mammalian cells using alfalfa mosaic virus. Pflugers Arch. 2007;454(1):155-63.
40. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat. Methods 2012;9(4):357-9.
41. The 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 2010;467(7319):1061-73.
42. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164.
43. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, Flanagan A, Teague J, Futreal PA, Stratton MR, Wooster R. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br. J. Cancer 2004;91(2):355-8.